Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022
31 October 2022 - 10:00PM
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a
clinical-stage biopharmaceutical company, today announced that it
will host a live conference call and audio webcast on Monday,
November 7, 2022, at 4:30 p.m. ET to report financial results for
the third quarter ended September 30, 2022, and to provide a
business update.
To access the live conference call, participants may register
here. While not required, it is recommended that participants join
the call ten minutes prior to the scheduled start. A live webcast
of the call will also be available under "Events and Presentations"
in the Investor Relations section of the Atea Pharmaceuticals
website at https://ir.ateapharma.com/. An archived webcast will be
available on Atea Pharmaceuticals’ website approximately two hours
after the conference call and will remain available for at least 90
days following the event.
About Atea Pharmaceuticals
Atea is a clinical stage biopharmaceutical company focused on
discovering, developing and commercializing oral therapies to
address the unmet medical needs of patients with severe diseases.
Leveraging the Company’s deep understanding of antiviral drug
development, nucleos(t)ide chemistry, biology, biochemistry and
virology, Atea has built a proprietary nucleos(t)ide prodrug
platform to develop novel product candidates to treat single
stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent
cause of severe viral diseases. Atea plans to continue to build its
pipeline of antiviral product candidates by augmenting its
nucleos(t)ide platform with other classes of antivirals that may be
used in combination with its nucleos(t)ide product candidates.
Currently, Atea is focused on the development of orally-available
antiviral agents for difficult-to-treat, severe viral infections,
including severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), the virus that causes COVID-19, hepatitis C virus
(HCV), dengue virus and respiratory syncytial virus (RSV). For more
information, please visit www.ateapharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding the timing of Atea’s earnings call for the quarter ended
September 30, 2022. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to the
important factors discussed under the caption “Risk Factors” in our
Annual Report on Form 10-K for the year ended December 31, 2021 and
our other filings with the SEC. Any such forward-looking statements
represent management’s estimates as of the date of this press
release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
Contacts
Jonae BarnesSVP, Investor Relations and Corporate
Communications617-818-2985Barnes.jonae@ateapharma.com
Will O’ConnorStern Investor Relations
212-362-1200will.oconnor@sternir.com
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Mar 2023 to Mar 2024